BMYMP News and Press, Bristol-Myers Squibb $2Pr From 01/10/24

2024-01-10 08:01:12 ET Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 bil...

2024-01-08 13:08:08 ET Bristol-Myers Squibb Company (BMY) J.P. Morgan 42nd Annual Healthcare Conference Call January 08, 2024, 10:30 AM ET Company Participants Chris Boerner - Chief Executive Officer Conference Call Participants Chris Schott - JPMorgan ...

2024-01-04 18:48:11 ET Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference January 04, 2024, 11:00 AM ET Company Participants Adam Lenkowsky - CCO Conference Call Participants Chris Shibutani - Goldman Sachs Present...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-28 16:41:16 ET Summary ABM Industries extends its 56-year streak of dividend increases with a 2.3% increase. Companies that consistently increase their dividends perform better than those that don't. The article provides insights on upcoming dividend increases and comp...

2023-12-25 05:42:51 ET Summary Mirati Therapeutics is a biotech company specializing in oncology therapies, with its star product being adagrasib for treating lung cancer. Bristol Myers Squibb is set to acquire Mirati Therapeutics for $4.8 billion, with shareholders receiving a Co...

2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...

2023-12-17 02:00:00 ET Summary SystImmune out-licenses global rights for a bispecific ADC to Bristol Myers Squibb in an $8.4 billion agreement. Evive Biotech forms an antibody discovery collaboration with Nona Biosciences to accelerate the process of antibody discovery and drug de...

2023-12-06 13:16:08 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-11-21 13:48:38 ET Summary VTRS reported Q3-2023 earnings in line with estimates, with total sales down 3.3%. Adjusted EBITDA fell again, and new product launches are not delivering the same margins as the old business. We look at the progress made since its listing and te...